Table 1.
Description of active grants in rare cancer clusters identified based on SEER statistical commonalities
| Cluster A: Low incidence, mortality, and prevalence; lower and worsening survival | Cluster B: Higher incidence, mortality and prevalence; average to better survival | Cluster C: Higher and worsening incidence, highest mortality, lowest and worsening survival; average prevalence | Cluster D: Low and worsening incidence and mortality; average to better survival; average prevalence | Cluster E: Highest incidence, average to better and improving survival; highest prevalence | |
|---|---|---|---|---|---|
| Number of cancers in cluster | 12 | 4 | 7 | 16 | 6 |
| Cancer types in cluster | Ureter, retroperitoneum, vagina, nose/nasal cavity/middle ear, nasopharynx, floor of mouth, larynx, peritoneum, hypopharynx, mesothelioma, gallbladder, acute monocytic leukemia | Ovary, cervix, chronic lymphocytic leukemia, rectum | Pancreas, liver/bile duct, brain/nervous system, stomach, myeloma, ill-defined and unspecified, esophagus | Small intestine, tongue, anus/anal canal/anorectum, tonsil, oropharynx, chronic myeloid leukemia, acute myeloid leukemia, Kaposi sarcoma, bones/joints, penis, salivary gland, vulva, soft tissue, eye, lip, pleura | Acute lymphocytic leukemia, Hodgkin lymphoma, testis, non-Hodgkin lymphoma, kidney/renal pelvis, thyroid |
| Number of active grants (based on cancer type)a | 2 | 43 | 33 | 17 | 18 |
| Number of active grants a per cancer type | 0.17 | 10.8 | 4.7 | 1.1 | 3.0 |
| Number of interventional active grants | 1 | 10 | 4 | 1 | 3 |
| Number of observational study active grants | 1 | 33 | 29 | 16 | 15 |
a
grant could be counted in more than one cluster if it included more than one cancer type as a focus